RedHill Biopharma (RDHL) Income from Non-Controlling Interests (2012 - 2022)
RedHill Biopharma (RDHL) posted quarterly Income from Non-Controlling Interests of $0.06 for Q3 2022, up 20.0% year-over-year from $0.05 in Q3 2021, and up 200.0% quarter-over-quarter from $0.02 in Q2 2022.
RedHill Biopharma (RDHL) Income from Non-Controlling Interests (2012 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Income from Non-Controlling Interests for 11 consecutive years, with $0.06 the latest figure, recorded in Q3 2022.
- In Q3 2022, Income from Non-Controlling Interests rose 20.0% year-over-year to $0.06; the TTM figure through Dec 2022 stood at $0.11 (down 47.62% YoY), while the FY2022 annual figure was $0.12, down 42.86% from the prior year.
- Income from Non-Controlling Interests grew to $0.06 in Q3 2022 per RDHL's latest filing, from $0.02 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $0.07 in Q4 2020 and bottomed at $0.02 in Q2 2022.
- Historically, Income from Non-Controlling Interests has averaged $0.04 across 5 years, with a median of $0.05 in 2021.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests jumped 133.33% — and 2022, when it plunged 66.67%.
- RedHill Biopharma's Income from Non-Controlling Interests stood at $0.03 in 2018, then grew by 0.0% to $0.03 in 2019, then surged by 133.33% to $0.07 in 2020, then slipped by 28.57% to $0.05 in 2021, then advanced by 20.0% to $0.06 in 2022.
- Business Quant data shows RDHL's Income from Non-Controlling Interests at $0.06 in Q3 2022, $0.02 in Q2 2022, and $0.03 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.02 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.05 |
| Jun 30, 2021 | 0.06 |
| Mar 31, 2021 | 0.05 |
| Dec 31, 2020 | 0.07 |
| Sep 30, 2020 | 0.05 |
| Jun 30, 2020 | 0.04 |
| Mar 31, 2020 | 0.05 |
| Dec 31, 2019 | 0.03 |
| Sep 30, 2019 | 0.03 |
| Jun 30, 2019 | 0.04 |
| Mar 31, 2019 | 0.03 |
| Dec 31, 2018 | 0.03 |
| Sep 30, 2018 | 0.04 |
| Jun 30, 2018 | 0.05 |
| Mar 31, 2018 | 0.05 |
| Dec 31, 2017 | 0.05 |